Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Amer M. Zeidan, MBBS, MHS, Gary J. Schiller, MD, Tara L. Lin, MD, Pamela S. Becker, MD PhD, Prapti A. Patel, MD, Eunice S. Wang, MD, Alexander I. Spira, PhD MD FACP, Michaela L. Tsai, MD, Maya Ridinger, Peter J Croucher, PhD, Mark Erlander, PhD, Sandra L Silberman, MD PhD

Blood (2019) 134 (Supplement_1): 230.

https://doi.org/10.1182/blood-2019-126262

Published: 2019

Journal Articles

Updated Phase 1 Results of a First-in-Human Open-Label Study of Lcar-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (Bcma)

Blood (2019) 134 (Supplement_1): 1858.

https://doi.org/10.1182/blood-2019-130008

Published: 2019

Journal Articles

Efficacy and Safety of Direct Oral Anticoagulants in Patients with Cirrhosis— Single Institution Experience

Kamila I. Cisak, MD, Dennis Asante, MS, Diane E. Grill, MS, Aneel A. Ashrani, MD, M.S.

Blood (2018) 132 (Supplement 1): 2525.

https://doi.org/10.1182/blood-2018-99-117607

Published: 2018

Journal Articles

A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)

Blood (2018) 132 (Supplement 1): 705.

https://doi.org/10.1182/blood-2018-99-117671

Published: 2018

Journal Articles

Refractory Autoimmune Hemolytic Anemia Following Hematopoietic Stem Cell Transplant (HSCT) in the Setting of Impaired Immune Reconstitution Among Pediatric HSCT Recipients

Lauren Scherer, MD, Amanda Bell Grimes, MD, Taylor Kim, MD, Caridad A. Martinez, MD

Blood (2018) 132 (Supplement 1): 4580.

https://doi.org/10.1182/blood-2018-99-120277

Published: 2018

Journal Articles

A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results

Aref Al-Kali, MD, Raoul Tibes, MD PhD, Jeanne Palmer, MD, Hassan B. Alkhateeb, MD, Mrinal M. Patnaik, MD MBBS, Kebede H. Begna, MD, Naseema Gangat, MBBS, Pamela Atherton, Shujun Liu, PhD, Rong He, MD, Shahrukh K. Hashmi, MD MPH, Mark R. Litzow, MD

Blood (2018) 132 (Supplement 1): 1443.

https://doi.org/10.1182/blood-2018-99-118552

Published: 2018

Journal Articles

Folate-Dependent Normocytic Anemia Caused By a Hypomorphic Mutation in SLC19A1 gene

Michael Svaton, MD, Karolina Skvarova Kramarzova, MSc, PhD, Veronika Kanderova, MSc, PhD, Petr Smisek, MD, Pavel Jesina, MSc, MD, PhD, Jakub Krijt, MSc, Blanka Stiburkova, MSc, PhD, Andrea Mancikova, MSc, Robert Dobrovolny, MSc, PhD, Violeta Bakardjieva-Mihaylova, MSc, Elena Vodickova, MD, Jan Stuchly, MSc, Tomas Kalina, MD PhD, Jan Stary, MD PhD, Jan Trka, MD PhD, Eva Fronkova, MD PhD, Viktor Kozich, MD PhD

Blood (2018) 132 (Supplement 1): 502.

https://doi.org/10.1182/blood-2018-99-113501

Published: 2018

Journal Articles

Incidence of Post-Hematopoietic Stem Cell Transplantation (HSCT) Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) without Hyperbilirubinemia at Diagnosis and Efficacy of Defibrotide in an Expanded-Access Program

Selim Corbacioglu, MD, Nancy A. Kernan, Antonio Pagliuca, Robert Ryan, William Tappe, Paul Richardson

Blood (2018) 132 (Supplement 1): 2080.

https://doi.org/10.1182/blood-2018-99-117173

Published: 2018

Journal Articles

Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome

Claire E McKinley, BSc, Stephen John Richards, PhD FRCPath, Talha Munir, Morag Griffin, Lindsay D Mitchell, MBChB, MRCP(UK), FRCPath, Louise Arnold, Kathryn Riley, Nicola Copeland, Darren J Newton, PhD, Anita Hill, MBChB (Hons), PhD, Peter Hillmen, MBChB, PhD

Blood (2017) 130 (Supplement 1): 3471.

https://doi.org/10.1182/blood.V130.Suppl_1.3471.3471

Published: 2017

Journal Articles

Feasibility and Outcome of Late Intensification with Native L-Asparaginase for Acute Lymphoblastic Leukemia in the Elderly: A Single Center Experience

Francois Xavier Gros, MD, Pierre-Yves Dumas, MD, Edouard Forcade, MD, Claire Calmettes, MD, Margot Robles, MD, Vincent Servant, PharmD, Nicolas Lechevalier, PharmD, Audrey Bidet, PharmD, Noel Milpied, Arnaud Pigneux, MD PhD, Thibaut Leguay, MD

Blood (2017) 130 (Supplement 1): 1296.

https://doi.org/10.1182/blood.V130.Suppl_1.1296.1296

Published: 2017

Journal Articles

A Dose-Finding Study of Lenalidomide As Post-Remission Therapy for Older Adults with Acute Myeloid Leukemia (AML)

Matthew C. Foster, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Benjamin G. Vincent, MD, Melissa Matson, AGPCNP-BC, Karen McKinnon, PhD, Shannon Reisdorf, BS, Jack Zhang, RN, Will Pulley, BA, Hyman Muss, MD, Anastasia Ivanova, PhD, Joshua F Zeidner, MD

Blood (2017) 130 (Supplement 1): 2631.

https://doi.org/10.1182/blood.V130.Suppl_1.2631.2631

Published: 2017

Journal Articles

Review of Patient Reported Symptoms in Patient Recieving Photopheresis (ECP) for Chronic Graft Vs Host Disease (CGvHD) Using the Lee Score

Arun Alfred, Catriona Barker, Cherie Rushton, BA, MSc, RN, Peter Taylor

Blood (2017) 130 (Supplement 1): 5644.

https://doi.org/10.1182/blood.V130.Suppl_1.5644.5644

Published: 2017

Journal Articles

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

Blood (2017) 130 (Supplement 1): 1377.

https://doi.org/10.1182/blood.V130.Suppl_1.1377.1377

Published: 2017

Journal Articles

Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML

Naval Daver, MD, Daniel A. Pollyea, MD, Karen W.L. Yee, MD, Pierre Fenaux, MD PhD, Joseph M. Brandwein, MD FRCPC, Norbert Vey, Giovanni Martinelli, Kevin R Kelly, MD PhD, Gail J. Roboz, MD, Jacqueline S. Garcia, Arnaud Pigneux, MD PhD, Smita Kshirsagar, Monique Dail, Jue Wang, Mehrdad Mobasher, Lin-Chi Chen, Wan-Jen Hong, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 813.

https://doi.org/10.1182/blood.V130.Suppl_1.813.813

Published: 2017

Journal Articles

Impact of GBT440 on Unconjugated Bilirubin and Jaundice in Sickle Cell Disease: A Patient Case Report

Paul Telfer, FRCPath, MD, Josh Lehrer, MD MPhil, FACC, Irene Agodoa, MD, Marzena Jurek, MS, Kathleen M Fox, PhD, Laurie Burke, BPharm, MPH, Noel Landsman, Dip.Nur (SA), Timothy Mant, MB, FFPM, FRCP

Blood (2017) 130 (Supplement 1): 4779.

https://doi.org/10.1182/blood.V130.Suppl_1.4779.4779

Published: 2017

Journal Articles

Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for RRMM: Initial Safety and Efficacy Report from a Clinical Pilot Study

Lingzhi Yan, Jingjing Shang, Liqing Kang, Xiaolan Shi, Jin Zhou, Song Jin, Weiqin Yao, Ying Yao, Guanghua Chen, Ziling Zhu, Huirong Chang, Depei Wu, MD, Lei Yu, Chengcheng Fu

Blood (2017) 130 (Supplement 1): 506.

https://doi.org/10.1182/blood.V130.Suppl_1.506.506

Published: 2017

Journal Articles

Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

Blood (2016) 128 (22): 1639.

https://doi.org/10.1182/blood.V128.22.1639.1639

Published: 2016

Journal Articles

A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1 R132 Mutations

Blood (2016) 128 (22): 1073.

https://doi.org/10.1182/blood.V128.22.1073.1073

Published: 2016

Journal Articles

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

Tycel Phillips, MD, Mark Brunvand, MD, Andy Chen, MD PhD, Oliver Press, MD PhD, James Essell, MD, Annalisa Chiappella, MD, Catherine Diefenbach, MD, Surai Jones, MS Biostat, Jamie Hirata, PharmD, Ian W. Flinn, MD PhD

Blood (2016) 128 (22): 622.

https://doi.org/10.1182/blood.V128.22.622.622

Published: 2016

Journal Articles

Impact on Outcomes of Baseline Bilirubin in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Receiving Defibrotide Treatment: A Post-Hoc Analysis

Paul G. Richardson, MD, Angela R. Smith, MD, Brandon M. Triplett, MD, Nancy A. Kernan, MD, Stephan A. Grupp, MD PhD, Joseph H. Antin, MD, Leslie Lehmann, MD, Wei Liang, PhD, Robin Hume, MS, William Tappe, MD, Robert J. Soiffer, MD

Blood (2016) 128 (22): 2213.

https://doi.org/10.1182/blood.V128.22.2213.2213

Published: 2016

NARROW

Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Updated Phase 1 Results of a First-in-Human Open-Label Study of Lcar-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (Bcma)

Efficacy and Safety of Direct Oral Anticoagulants in Patients with Cirrhosis— Single Institution Experience

A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)

Refractory Autoimmune Hemolytic Anemia Following Hematopoietic Stem Cell Transplant (HSCT) in the Setting of Impaired Immune Reconstitution Among Pediatric HSCT Recipients

A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results

Folate-Dependent Normocytic Anemia Caused By a Hypomorphic Mutation in SLC19A1 gene

Incidence of Post-Hematopoietic Stem Cell Transplantation (HSCT) Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) without Hyperbilirubinemia at Diagnosis and Efficacy of Defibrotide in an Expanded-Access Program

Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome

Feasibility and Outcome of Late Intensification with Native L-Asparaginase for Acute Lymphoblastic Leukemia in the Elderly: A Single Center Experience

A Dose-Finding Study of Lenalidomide As Post-Remission Therapy for Older Adults with Acute Myeloid Leukemia (AML)

Review of Patient Reported Symptoms in Patient Recieving Photopheresis (ECP) for Chronic Graft Vs Host Disease (CGvHD) Using the Lee Score

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML

Impact of GBT440 on Unconjugated Bilirubin and Jaundice in Sickle Cell Disease: A Patient Case Report

Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for RRMM: Initial Safety and Efficacy Report from a Clinical Pilot Study

Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

A Phase I Study of IDH305 in Patients with Advanced Malignancies Including Relapsed/Refractory AML and MDS That Harbor IDH1 R132 Mutations

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

Impact on Outcomes of Baseline Bilirubin in Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Receiving Defibrotide Treatment: A Post-Hoc Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only